Geode Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.14M Buy
536,575
+30,795
+6% +$73.2K ﹤0.01% 3321
2025
Q4
$1.23M Buy
505,780
+5,257
+1% +$18.6K ﹤0.01% 3316
2025
Q3
$1.9M Buy
500,523
+5,180
+1% +$15.2K ﹤0.01% 3195
2025
Q2
$1.23M Sell
495,343
-470,256
-49% -$906K ﹤0.01% 3269
2025
Q1
$1.5M Buy
965,599
+6,283
+0.7% +$13.2K ﹤0.01% 3156
2024
Q4
$2.05M Buy
959,316
+14,439
+2% +$41.4K ﹤0.01% 3112
2024
Q3
$4.11M Buy
944,877
+102,445
+12% +$557K ﹤0.01% 2864
2024
Q2
$3.93M Buy
842,432
+459,819
+120% +$2.47M ﹤0.01% 2857
2024
Q1
$1.94M Buy
382,613
+32,167
+9% +$130K ﹤0.01% 3123
2023
Q4
$985K Buy
350,446
+26,155
+8% +$61.4K ﹤0.01% 3363
2023
Q3
$931K Buy
324,291
+53,084
+20% +$196K ﹤0.01% 3352
2023
Q2
$1.37M Buy
271,207
+779
+0.3% +$1.59K ﹤0.01% 3235
2023
Q1
$511K Buy
270,428
+5,138
+2% +$11.8K ﹤0.01% 3637
2022
Q4
$477K Buy
265,290
+743
+0.3% +$1.34K ﹤0.01% 3679
2022
Q3
$447K Buy
264,547
+17,839
+7% +$55K ﹤0.01% 3778
2022
Q2
$606K Sell
246,708
-185,316
-43% -$431K ﹤0.01% 3653
2022
Q1
$1.2M Buy
432,024
+35,857
+9% +$131K ﹤0.01% 3530
2021
Q4
$2.11M Buy
396,167
+46,187
+13% +$323K ﹤0.01% 3338
2021
Q3
$2.96M Sell
349,980
-9,622
-3% -$95K ﹤0.01% 3187
2021
Q2
$4.38M Buy
359,602
+62,165
+21% +$1.23M ﹤0.01% 2984
2021
Q1
$7.21M Buy
297,437
+27,512
+10% +$742K ﹤0.01% 2585
2020
Q4
$8.65M Buy
269,925
+22,199
+9% +$729K ﹤0.01% 2273
2020
Q3
$7.49M Buy
247,726
+65,962
+36% +$2.01M ﹤0.01% 2144
2020
Q2
$7.66M Buy
181,764
+91,367
+101% +$3.36M ﹤0.01% 2090
2020
Q1
$2.25M Buy
+90,397
New +$2.75M ﹤0.01% 2609

Other funds holding BDTX

Geode Capital Management's BDTX Position: Q1 2026 in Review

Geode Capital Management increased its Black Diamond Therapeutics (BDTX) stake by 6.1% in Q1 2026, buying an estimated $73.2K and bringing the position to 536,575 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #3321.

Geode Capital Management first reported a position in BDTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $8.65M in Q4 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Geode Capital Management held 536,575 shares of Black Diamond Therapeutics worth $1.14M as of Q1 2026.
  • Geode Capital Management bought 30,795 Black Diamond Therapeutics shares in Q1 2026, an estimated $73.2K.
  • Black Diamond Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3321 holding.
  • Geode Capital Management first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Geode Capital Management's Black Diamond Therapeutics position peaked at $8.65M in Q4 2020.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.